Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
3 Results for "
Cullin-dependent
" in MedChemExpress (MCE) Product Catalog:
Products (3)
3 Results for "Cullin-dependent" in MCE Product Catalog:
Cat. No.: HY-187338
Target:
Research Areas:
CRBN ligand-908 is a cereblon (CRBN) ligand and also a HaloTag-binding degrader. CRBN ligand-908 competes with fluorescent lenalidomide ligands for binding to full-length CRBN protein. CRBN ligand-908 contains a chlorohexyl group that covalently reacts with HaloTag fused to target proteins. CRBN ligand-908 induces degradation of HaloTag-fused FAK, endogenous MARC1, and BRD4 proteins. CRBN ligand-908 is a proteasome- and Cullin-dependent degrader. CRBN ligand-908 does not induce degradation of the novel CRBN substrates GSPT1, SALL4, or CSNK1α. CRBN ligand-908 can be used to synthesize PROTACs, such as HaloPROTAC 4 (HY-187337) .
Cat. No.: HY-210438
Target:
Research Areas:
L013 is an orally active and selective NRF2 PROTAC degrader. L013 directly binds to the NRF2 protein and promotes NRF2 ubiquitination and UPS-related degradation through a Cullin-dependent, CRBN-related process. L013 inhibits RNA polymerase II transcriptional elongation and downregulates NFE2L2 transcript levels. L013 selectively reduces NRF2 protein/mRNA and inhibits proliferation/colony formation in esophageal squamous cell carcinoma cells with NRF2 hyperactivation. L013 inhibits tumor growth in the KYSE150 esophageal squamous cell carcinoma xenograft mouse model and reduces intratumoral NRF2 and Ki-67 protein levels. L013 can be used for research on esophageal squamous cell carcinoma and lung squamous cell carcinoma .
Cat. No.: HY-187396
Target:
Research Areas:
FD1-C10-CB is a PROTAC degrader targeting the BRD4 protein. FD1-C10-CB binds to FEM1B to form a ternary complex with BRD4, achieving FEM1B-dependent degradation of BRD4 via the ubiquitin-proteasome system. FD1-C10-CB binds to CD36 to mediate endocytic cellular delivery, thereby enhancing its degrading activity. FD1-C10-CB mediates protein degradation through the Cullin-dependent ubiquitin-proteasome pathway, rather than the lysosomal autophagy pathway. FD1-C10-CB induces a decrease in BRD4 protein levels, and its degrading activity is competitively inhibited by FL47 or JQ1. FD1-C10-CB can be used in the research of breast cancer and osteosarcoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
